The 36-month beta value for HEPA is also noteworthy at 1.91. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HEPA is 10.92M, and at present, short sellers hold a 5.93% of that float. The average trading volume of HEPA on April 29, 2025 was 3.89M shares.
HEPA) stock’s latest price update
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has seen a rise in its stock price by 4.51 in relation to its previous close of 0.29. However, the company has experienced a 7.98% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-14 that Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m.
HEPA’s Market Performance
Hepion Pharmaceuticals Inc (HEPA) has seen a 7.98% rise in stock performance for the week, with a -36.99% decline in the past month and a -97.28% plunge in the past quarter. The volatility ratio for the week is 13.39%, and the volatility levels for the past 30 days are at 26.85% for HEPA. The simple moving average for the past 20 days is -19.36% for HEPA’s stock, with a -98.72% simple moving average for the past 200 days.
Analysts’ Opinion of HEPA
Many brokerage firms have already submitted their reports for HEPA stocks, with ROTH Capital repeating the rating for HEPA by listing it as a “Buy.” The predicted price for HEPA in the upcoming period, according to ROTH Capital is $14 based on the research report published on July 20, 2020 of the previous year 2020.
HEPA Trading at -87.91% from the 50-Day Moving Average
After a stumble in the market that brought HEPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.62% of loss for the given period.
Volatility was left at 26.85%, however, over the last 30 days, the volatility rate increased by 13.39%, as shares sank -22.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -96.36% lower at present.
During the last 5 trading sessions, HEPA rose by +19.03%, which changed the moving average for the period of 200-days by -99.36% in comparison to the 20-day moving average, which settled at $0.3767. In addition, Hepion Pharmaceuticals Inc saw -98.71% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HEPA
The total capital return value is set at 12.64. Equity return is now at value -487.03, with -133.45 for asset returns.
Based on Hepion Pharmaceuticals Inc (HEPA), the company’s capital structure generated 2.8 points at debt to capital in total, while cash flow to debt ratio is standing at -6.28. The debt to equity ratio resting at -1.56. The interest coverage ratio of the stock is -4448.51.
Currently, EBITDA for the company is -19.35 million with net debt to EBITDA at -0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.51.
Conclusion
In summary, Hepion Pharmaceuticals Inc (HEPA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
